Click on image to view larger version.

Figure 1 (A) Kaplan-Meier curves for mortality in the valsartan (dotted line) and placebo (solid line) groups (n = 185 and 181, respectively) without angiotensin-converting enzyme (ACE) inhibitor background therapy (p = 0.017 by log-rank test). (B) Kaplan-Meier curves for the combined end point of mortality and morbidity in the valsartan (dotted line) and placebo (solid line) groups without ACE inhibitor background therapy (p < 0.001 by the log-rank test). Risk ratio (RR) and 95% confidence interval (CI) obtained using Cox regression.